

IN THE CLAIMS:

Please cancel claims 1 - 14 without prejudice or disclaimer and add the following claims.

Ind C2 --15. A method of treating a subject having a disease caused by interleukin-6 (IL-6) production comprising administering to said subject a therapeutically effective amount of an antibody to an IL-6 receptor in a pharmaceutically acceptable carrier.

16. The method according to claim 15, wherein said disease is plasmacytosis.
17. The method according to claim 16, wherein said plasmacytosis is induced by rheumatism.
18. The method according to claim 16, wherein said plasmacytosis is induced by Castelman's disease.
19. The method according to claim 15, wherein said disease is hyperimmunoglobulinemia.
20. The method according to claim 15, wherein said disease is anemia.
21. The method according to claim 15, wherein said disease is nephritis.
- B 3 22. The method according to claim 21, wherein said nephritis is mesangium proliferative nephritis.
23. The method according to claim 15, wherein said disease is cachexia.
24. The method according to claim 15, wherein said antibody is a monoclonal antibody.

Ind C3 25. The method according to claim 24, wherein said monoclonal antibody is the PM-1 antibody produced by hybridoma PM-1, accession number FERM BP-2998.

26. The method according to claim 24, wherein said monoclonal antibody is a chimeric antibody comprising the variable immunoglobulin heavy and light chains from a murine monoclonal antibody to an IL-6 receptor and the constant immunoglobulin heavy and light chains from a human monoclonal antibody.

27. The method according to claim 24, wherein said monoclonal antibody is a humanized murine monoclonal antibody to an IL-6 receptor.

Ind C4 28. The method according to claim 27, wherein said humanized murine monoclonal antibody to an IL-6 receptor is a humanized PM-1 antibody, wherein the PM-1 antibody prior to humanization is produced by hybridoma PM-1, accession number FERM BP-2998.--